FAP-Targeted Nanoparticle Mapping for Precise Tumor Margins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical imaging technologies fail to provide adequate spatial resolution for identifying tumor boundaries and margins, leading to incomplete surgical resections and reduced efficacy of non-surgical treatments due to inaccurate tumor volume estimation, resulting in high recurrence rates and severe side effects.
Innovation Solution
Development of nanoparticulate materials with a copolymeric steric stabilizer and mapping moiety that selectively bind to fibroblast activation protein (FAP) expressed in tumor microenvironments, enhancing accumulation and improving imaging techniques like MRI and radiotherapy to accurately map tumor margins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional medical imaging techniques (PET-PSMA, mpMRI) are used to identify tumor boundaries, then the imaging process is non-invasive and can be performed externally, but the spatial resolution is insufficient leading to underestimation of tumor volume by 9-20%
Solution Approach 1:
The patent introduces nanoparticulate materials as intermediary agents that accumulate in the tumor microenvironment and provide enhanced imaging contrast. These nanoparticles serve as mediators between the imaging system and the tumor tissue, enabling more precise visualization of tumor margins without requiring complex surgical exploration or invasive procedures. The nanoparticles bind to FAP-expressing cells and provide signal enhancement for imaging modalities like MRI, thereby improving measurement precision while maintaining relatively simple imaging system requirements.
2Manufacturing precision
If surgical tumour resection is performed to achieve complete tumour removal, then tumour clearance is maximized, but surgical margins are difficult to identify leading to positive margins and regional recurrence
Solution Approach 1:
The patent employs imaging contrast mechanisms that effectively create visual differentiation between tumor and normal tissue. The nanoparticulate materials accumulate preferentially in the tumor microenvironment and provide enhanced signal for imaging modalities, creating a visual 'color change' or contrast difference that allows surgeons to clearly identify tumor margins during resection. This enables precise surgical margins to be achieved with accurate visual guidance.
3Object-affected harmful factors
If non-surgical treatment modalities (radiotherapy, brachytherapy, focal therapy) are used to reduce side effects, then patient quality of life is preserved, but treatment efficacy is reduced due to inaccurate tumor volume characterization
Solution Approach 1:
The patent applies nanoparticulate materials prior to non-surgical treatment to pre-characterize the tumor volume and margins with high precision. This preliminary action of accurate tumor mapping allows treatment planners to define precise treatment volumes, ensuring that the full extent of the tumor is targeted while minimizing exposure of normal tissues. This preliminary characterization enables non-surgical modalities to achieve both reduced side effects and maintained efficacy.
4Reliability
If focal therapy is performed with extended ablation margins to compensate for imaging limitations, then tumor coverage is improved, but normal tissue exposure increases leading to higher recurrence rates
Solution Approach 1:
The patent replaces the mechanical approach of extending ablation margins with a biology-based targeting approach. Instead of blindly extending treatment zones to compensate for imaging limitations, the nanoparticles provide biological targeting through FAP binding, allowing precise delineation of tumor margins. This substitution enables treatment planning based on actual tumor biology rather than arbitrary margin extensions, thereby improving reliability while reducing normal tissue toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticulate materials enhance the accuracy of tumor margin identification, allowing for more precise surgical resections and targeted non-surgical treatments, reducing recurrence rates and side effects.
Implementation Method 1
copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid
Implementation Method 2
one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP)
Implementation Method 3
nanoparticulate material selectively accumulates in the tumour microenvironment
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
Nanoparticulate material suitable for administration to a subject, the nanoparticulate material having bound to its surface: (a) copolymeric steric stabiliser that promotes dispersion of the nanoparticulate material in a liquid, wherein the copolymeric steric stabiliser comprises (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric steric stabiliser to the nanoparticulate material, and (ii) a steric stabilising polymer segment that is different from the anchoring polymer segment, and (b) copolymeric mapping moiety comprising (i) an anchoring polymer segment having one or more binding groups that bind the copolymeric mapping moiety to the nanoparticulate material, (ii) one or more mapping groups comprising an agent that specifically binds to fibroblast activation protein (FAP), and (iii) a coupling polymer segment that is different to the anchoring polymer segment, wherein the coupling polymer segment couples the anchoring polymer segment to the one or more mapping groups.